FTC Reaches Settlement With CVS Caremark to Curb Insulin Rebate Pract…

The FTC has settled with CVS Caremark over insulin rebate practices that inflated patient costs, requiring the pharmacy benefit manager to pass through more rebates to patients and reduce spread pricing on insulin. This settlement directly targets the middleman markup that has driven insulin affordability crises. If you're building insulin access or pricing transparency software, PBMs just lost their legal cover to bury rebates. The door to displace CVS, Cigna, and Optum in diabetes management just opened wider - call the large health plans and employers who fund insulin coverage this week.